Oracle Runs

Oracle findings and outcome history for Assessment of Psilocybin (TRP-8802) in Concert With Psychotherapy in Patients With Irritable Bowel Syndrome (IBS) (NCT06206265).

Runs

Findings

Latest Run

Apr 6, 2026, 2:57 PM

All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

NO_DECISIONDismissed80% confidenceGrok 4.20 (xAI)

Will the results be positive?

Trial active, not recruiting, primary completion Mar 2026; no final results available. Dec 2024 interim data from sponsor ASX release frames early positive safety/efficacy signals (75% reduction in pain/anxiety in small cohort) in this exact Phase 2a IBS TRP-8802 trial at MGH, but interim not 'overall readout'; full topline pending.

Found Apr 6, 2026, 2:59 PMReviewed Apr 6, 2026, 3:00 PM

Web Searchlistcorp.comDec 18, 2024, 12:00 AM

Positive interim results in Phase 2a TRP-8802 IBS trial

ASX announcement titled 'Positive interim results in Phase 2a TRP-8802 IBS trial conducted at Massachusetts General Hospital'.

ClinicalTrialsclinicaltrials.gov

NCT06206265: Assessment of Psilocybin (TRP-8802) in IBS

Phase 2a trial by TRYP Therapeutics, status Active not recruiting, enrollment 14 actual, estimated primary completion 2026-03-01, no results posted.

Sponsorasx.com.auJan 30, 2025, 12:00 AM

ASX Release Dec 2024 Quarterly: Positive IBS interim

Positive interim from Phase 2a TRP-8802 IBS at MGH: 75% of treated patients achieved reduction in abdominal pain and GI anxiety; supports TRP-8803 but interim data.

NO_DECISIONDismissed100% confidenceGrok 4.20 (xAI)

Will the results be positive?

Trial active, primary completion est. Mar 2026. Only interim results reported Dec 2024: sponsor framed as 'positive' with 75% patients showing clinically meaningful reductions in abdominal pain and anxiety (not primary safety endpoints). No full readout; interim not 'overall public readout'.

Found Apr 6, 2026, 2:28 PMReviewed Apr 6, 2026, 2:41 PM

Web Searchlistcorp.comDec 18, 2024, 12:00 AM

Positive interim results in Phase 2a TRP-8802 IBS trial

ASX release: Positive interim results from Phase 2a TRP-8802 IBS trial at MGH. Study ongoing.

Web Searchclinicaltrials.gov

NCT06206265: Assessment of Psilocybin (TRP-8802) in IBS

Phase 2, active not recruiting, enrollment 14 actual, primary completion est. 2026-03-01. Site: Massachusetts General Hospital.

Web Searchsharesinvalue.com.auApr 11, 2025, 12:00 AM

Tryptamine Initiating Coverage Apr 2025

H2 2024 interim: 75% patients reported clinically meaningful decrease in abdominal pain and anxiety. IBS Phase 2a ongoing.

NO_DECISIONDismissed90% confidencemanual-chat-review

Will the results be positive?

ClinicalTrials.gov still lists this study as active not recruiting with no posted results, so there is not yet a clear public positive or negative trial readout.

Found Apr 4, 2026, 8:54 PMReviewed Apr 4, 2026, 10:33 PM

ClinicalTrialsclinicaltrials.govFeb 5, 2026, 12:00 AM

Study Details | NCT06206265 | ClinicalTrials.gov

ClinicalTrials.gov lists active not recruiting; primary completion 2026-03-01; hasResults=false on the latest posted update.

NO_DECISIONDismissed93% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No overall Phase 2 readout is publicly established. The trial record remains active with no results posted, and the sponsor’s public statement is only an interim 4-patient update. That is encouraging but incomplete, so it does not justify an overall positive/negative trial classification.

Found Apr 3, 2026, 4:30 PMReviewed Apr 3, 2026, 4:47 PM

ClinicalTrialsclinicaltrials.govFeb 5, 2026, 12:00 AM

Study Details | NCT06206265 | Assessment of Psilocybin (TRP-8802) in Concert With Psychotherapy in Patients With Irritable Bowel Syndrome (IBS)

ClinicalTrials.gov lists the Phase 2 study as Active, not recruiting, with estimated primary completion March 1, 2026, and states 'No Results Posted.'

Sponsorannouncements.asx.com.auJan 30, 2025, 12:00 AM

ASX Release

Tryp reported 'positive interim data' from the IBS Phase 2a study, but only four of up to 10 patients had been treated; 75% reported a clinically meaningful decrease in abdominal pain and GI-related anxiety.

NO_DECISIONDismissed94% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No overall Phase 2 readout is publicly available. The clearest trial-specific update is sponsor-reported interim data from 4/10 IBS patients described as encouraging, but the same source says the trial is ongoing. An ongoing/interim signal is insufficient to label the exact trial overall positive or negative.

Found Apr 1, 2026, 7:50 PMReviewed Apr 1, 2026, 8:21 PM

Web Searchbulletin.webull.comAug 29, 2025, 12:00 AM

Tryptamine Therapeutics Limited Annual Report 2025

Sponsor annual report says interim IBS results from 4 of 10 patients showed 75% had reduced abdominal pain and GI anxiety, called the initial results highly encouraging, and states the trial is ongoing.

Web Searchfdaaa.trialstracker.netJul 8, 2025, 12:00 AM

NCT06206265: An ongoing trial by TRYP Therapeutics

TrialTracker lists NCT06206265 as ongoing, with results status ongoing and no actual reporting date posted.

Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

No oracle outcome history is available for this trial yet.